molecules of the month

“compound 25”

mutant KRASG12C allosteric covalent inhibitor

orally efficacious in XG model

from optimization of literature starting point

J. Med. Chem. Feb. 5, 2020

AstraZeneca, Cambridge, UK

"compound 25"
1 min read

KRAS(G12C) inhibitor from AZ (AstraZeneca oral in vivo mutant KRAS(G12C) allosteric covalent inhibitor)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: